Affordable Access

Access to the full text

Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report

Authors
  • Umemura, Machiko1
  • Suda, Goki1, 2
  • Tsukamoto, Shihori1
  • Ebata, Ko1
  • Takahash, Shinjiro1
  • Sasaki, Takashi1
  • Nakajima, Sae1
  • Hirata, Koji1
  • Ozasa, Mariko1
  • Takano, Masatoshi1
  • Katagiri, Masaki1
  • Sakamoto, Naoya2
  • 1 Sapporo Hokuyu Hospital, Sapporo, Hokkaido, Japan , Sapporo (Japan)
  • 2 Hokkaido University, Sapporo, Hokkaido, Japan , Sapporo (Japan)
Type
Published Article
Journal
BMC Infectious Diseases
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Apr 27, 2021
Volume
21
Issue
1
Identifiers
DOI: 10.1186/s12879-021-06091-x
Source
Springer Nature
Keywords
License
Green

Abstract

BackgroundIn patients with hepatitis C virus (HCV) and malignant lymphoma, hepatitis C flare during R-CHOP can result in discontinuation of treatment. However, appropriate therapeutic strategies for managing hepatitis C flare during R-CHOP have not been established, and this issue is complicated by conflicting results regarding the use of direct-acting antivirals in patients with uncontrolled malignancies.Case presentationWe report the first case of effective and safe treatment with on-demand 8-week glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in a patient with diffuse large B-cell lymphoma (DLBCL). The patient completed five additional courses of R-CHOP without hepatic toxicity. A complete response of DLBCL and a sustained virological response were observed at 24 weeks after glecaprevir and pibrentasvir completion.ConclusionOn-demand, direct-acting antivirals could be a novel strategy for managing hepatitis C flare during R-CHOP.

Report this publication

Statistics

Seen <100 times